Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Savara Inc is a pharmaceutical company. The company develops novel therapies for the treatment of serious or life-threatening rare respiratory diseases. It offers products such as AeroVanc, for the treatment of persistent methicillin-resistant staphylococcus aureus and lung infection in cystic fibrosis patients; Molgradex, for the treatment of autoimmune pulmonary alveolar proteinosis and Aironite, an inhaled nebulized sodium nitrite solution to treat heart failure with preserved ejection fraction. All the business activity of the firm functions through the region of the United States.
Austin, TX, 78746